Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by RoyMax123on Jul 20, 2023 10:36am
68 Views
Post# 35549660

RE:Coactiv+ - no news, no sales update, total radio silence....

RE:Coactiv+ - no news, no sales update, total radio silence....
They already said in their last conf call that they need to ramp up the production before they start selling, so they hope to have revenue in Q4.
 
And since there's always some delays it probably mean Q1 next year at best.

francoisl13 wrote: It is amazing to see that KNE did not announce it's first sale of Coactiv+ in the USA (through Progenacare) yet. The deal with Progenacare was made prior to the FDA approval so, one would imagine that Progenacare customers were told in advance that the product was coming and still no news. KNE did not even bother to do a press release to confirm the receipt of the 500K upfront payment from Progenacare. I understand that the KNE team is rather small but investors communication is critical for a biotech of that size in order to keep the investment community interest and we fail big time on that front.
The above being said, it looks like we are on the right path in regards to products development, approval, trials, etc.... but need more to get the investment community interest.
GLTA  


<< Previous
Bullboard Posts
Next >>